BioAtla (BCAB) to Release Quarterly Earnings on Thursday

BioAtla (NASDAQ:BCAB) is expected to be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

BioAtla (NASDAQ:BCAB) last issued its earnings results on Thursday, August 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). On average, analysts expect BioAtla to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioAtla Stock Performance

Shares of BioAtla stock opened at $0.70 on Thursday. The firm has a market cap of $40.99 million, a PE ratio of -0.63 and a beta of 1.03. The firm’s 50-day simple moving average is $0.66 and its 200-day simple moving average is $0.49. BioAtla has a 1 year low of $0.24 and a 1 year high of $2.53.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BCAB. Weiss Ratings restated a “sell (d-)” rating on shares of BioAtla in a research note on Tuesday, October 14th. Citizens Jmp lowered shares of BioAtla from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 13th. Wall Street Zen upgraded shares of BioAtla to a “sell” rating in a research note on Saturday, September 6th. Finally, JMP Securities restated a “market perform” rating on shares of BioAtla in a research note on Wednesday, August 13th. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, BioAtla currently has a consensus rating of “Reduce”.

Institutional Investors Weigh In On BioAtla

A hedge fund recently bought a new stake in BioAtla stock. Woodline Partners LP purchased a new stake in shares of BioAtla, Inc. (NASDAQ:BCAB) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 76,324 shares of the company’s stock, valued at approximately $26,000. Woodline Partners LP owned about 0.13% of BioAtla at the end of the most recent quarter. 77.23% of the stock is currently owned by institutional investors and hedge funds.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.